Skip to main content
Shanghai Junshi Biosciences Co.,Ltd. logo

Shanghai Junshi Biosciences Co.,Ltd. — Investor Relations & Filings

Ticker · 688180 ISIN · CNE1000041Z1 LEI · 300300L36FLCKN0WXW06 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,065 across all filing types
Latest filing 2025-12-07 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688180

About Shanghai Junshi Biosciences Co.,Ltd.

https://www.junshipharma.com/

Shanghai Junshi Biosciences Co., Ltd. is an innovation-driven biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies. The company maintains a diverse pipeline targeting oncology, immunology, metabolic disorders, neurological diseases, and infectious diseases. A pioneer in its field, it developed Toripalimab, the first domestically produced anti-PD-1 monoclonal antibody to receive marketing approval in its home market. Its integrated R&D platform encompasses the entire drug development lifecycle, from initial discovery and clinical evaluation to large-scale manufacturing and global commercialization. The company collaborates with international partners to expand the reach of its innovative biologics, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates, aiming to provide effective and affordable treatment options for patients globally.

Recent filings

Filing Released Lang Actions
君实生物自愿披露关于拓益?新增适应症和君适达?纳入国家医保目录的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Shanghai Junshi Biosciences Co., Ltd. regarding the inclusion of two of its pharmaceutical products (拓益 and 君适达) in the national medical insurance catalog. It details the new indications for the drug 拓益 and the inclusion of 君适达 in the 2025 National Basic Medical Insurance Drug Catalog, effective from January 1, 2026. The document includes product descriptions, regulatory approvals, and the impact on the company, but it does not contain financial statements, earnings data, or detailed financial analysis. It is a regulatory announcement about product and insurance listing status, not a financial report or earnings release. The document length is 2833 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-12-07 Chinese
君实生物自愿披露关于偌考奇拜单抗注射液新药上市申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Shanghai Junshi Biosciences Co., Ltd. regarding the acceptance of a new drug marketing application by the National Medical Products Administration. It details the drug's basic information, clinical trial results, and risk warnings. The document is an official announcement about regulatory acceptance of a new drug application, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. The document length is short (1672 characters) and it serves as a regulatory announcement about a drug approval process. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-12-05 Chinese
君实生物关于持股5%以上股东减持股份结果公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding the results of a shareholding reduction by a shareholder holding more than 5% of the company's shares. It details the shareholder's holdings before and after the reduction, the number of shares reduced, the method of reduction (block trade), and compliance with relevant laws and regulations. There is no financial report, earnings data, or management discussion. The document is a formal disclosure of a major shareholding change, specifically a reduction in shares held by a significant shareholder. This fits the definition of a Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, not a full report or announcement of a report publication.
2025-12-04 Chinese
君实生物H股公告
Share Issue/Capital Change Classification · 95% confidence The document is a monthly report on changes in issued shares and share capital for Shanghai Junshi Biosciences Co., Ltd., submitted to the Hong Kong Stock Exchange. It details registered capital, issued shares, stock options, and confirmations related to compliance with listing rules. The document references the Listing Rules Chapter 19B and includes detailed tables of share movements and confirmations by company secretary. It is a regulatory monthly disclosure of share capital and shareholding changes, not a full financial report, earnings release, or management discussion. It is not an announcement of a report publication but the report itself. This fits the category of Share Issue/Capital Change (SHA) as it reports on share capital and share issuance changes.
2025-12-04 Chinese
君实生物关于持股5%以上股东权益变动触及5%刻度的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about changes in shareholding percentages by shareholders holding more than 5% of the company's shares. It details the decrease in shareholding from 5.0051% to 4.7129%, specifies the shareholders involved, and confirms that the change does not trigger mandatory tender offers or control changes. The document is titled as a "提示性公告" (prompting announcement) regarding shareholding changes and references a detailed report filed elsewhere. It does not contain financial statements or management discussion but focuses solely on shareholding notifications crossing the 5% threshold. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused on shareholding changes, not a full report or announcement of a report publication.
2025-12-03 Chinese
君实生物简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the changes in shareholding percentages of certain entities in Shanghai Junshi Biosciences Co., Ltd., specifically noting a decrease in shareholding below 5% due to H-share lending. The document includes detailed information about the shareholders, their shareholding before and after the change, the nature of the change, and legal compliance statements referencing Chinese securities laws and disclosure regulations. There is no indication that this is a full annual or interim financial report, audit report, or earnings release. It is not a proxy statement, AGM material, or management report. The document is a formal notification of a change in major shareholding levels, consistent with the definition of "Major Shareholding Notification (MRQ)" which covers notifications of changes in significant share ownership levels crossing thresholds. The document length and detail confirm it is the report itself, not just an announcement of a report publication or a certification. Therefore, the appropriate classification is MRQ.
2025-12-03 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.